Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer

Video

This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses 7-year follow-up data of the APT trial, which studied adjuvant paclitaxel/trastuzumab (TH) in early-stage patients with node-negative, HER2-positive breast cancer.

      Tolaney presented the study results (abstract 511) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

      Recent Videos
      Rhenium Obisbemeda Shows No DLTs and Improves Survival in Recurrent Glioma
      Rhenium Obisbemeda Shows No DLTs and Improves Survival in Recurrent Glioma
      Rhenium Obisbemeda Maintains and Distributes Radioisotopes in Glioma
      Rhenium Obisbemeda Maintains and Distributes Radioisotopes in Glioma
      Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
      Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation Status
      Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
      Clinical Data May Support PARP Inhibition in Somatic BRCA-Mutant TNBC
      According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
      Optimizing Peritoneal Carcinomatosis Treatment Strategies
      2 experts in this video
      MonumenTAL-1: Implications of Talquetamab, Prior TCR, and Sequencing for R/R MM
      Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
      Considerations After Initial CDK4/6 Inhibition in HR+/HER2- Breast Cancer
      2 experts in this video
      Insights From MonumenTAL-1: Impressions of Updated Efficacy Outcomes
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      VIDEO: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management
      VIDEO: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management
      Related Content
      Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

      FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

      Roman Fabbricatore
      June 22nd 2025
      Article

      Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

      PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

      PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      June 19th 2025
      Podcast

      Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

      TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

      TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

      Radhika Appaya;Mario Campone;Louise Emmett;Dejan Juric;Debasish Tripathy;Sonia Pernas;Monica Zuradelli;Kevin Perraud;Aleix Prat
      June 21st 2025
      Article

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      June 16th 2025
      Podcast

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

      Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

      Russ Conroy
      June 20th 2025
      Article

      Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

      26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

      26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

      Radhika Appaya;Paolo Tarantino, MD;Hope S. Rugo, MD;Guiseppe Curigliano;Joyce O’Shaughnessy, MD;Wolfgang Janni;Komal Jhaveri;Jason Mouabbi;Adam M. Brufsky, MD, PhD;Erika P. Hamilton, MD;Ruth M. O’Regan; Julia Kim;Liz Santarsiero;Murat Akdere;Fen Ye;Henry Owusu;Stephanie L. Graff, MD
      June 20th 2025
      Article